Therapeutics for Women's Health: Technologies and Global Markets

Feb 2022| BIO043G| BCC Publishing
Sample Report

Report Highlights

The global market for women’s health therapeutics should grow from $54.4 billion in 2021 to $70.8 billion by 2026 with a compound annual growth rate (CAGR) of 5.4% for the period of 2021-2026.

Report Includes

  • 58 data tables and 56 additional tables
  • An overview of the global market and technologies for women's health therapeutics
  • Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
  • Detailed study around women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden
  • Discussion on aging and women’s health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer
  • Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
  • Comprehensive company profiles of the leading players of the industry, including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen, and Merck

Report Scope

This report is an analytical business tool that comprehensively evaluates the global market for women’s health therapeutics. The format of the study is organized around the following topics:

  • Detailed study around women’s diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
  • Disease incidence and prevalence.
  • Regulatory structure of pharmaceutical industry.
  • Market characterization, unmet need, market size and segmentation.
  • Market drivers and restraints.
  • Detailed market projections through 2026.
  • Competition and market shares.
  • Pricing and reimbursement.
  • Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.
  • Observations and conclusions regarding the future of market for women’s health therapeutics.
  • Profiles of market participants and associations.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Therapeutics for Women's Health: Technologies and Global Markets258 $5,500 Free
Chapter- 1: Introduction9Free DownloadFree
Chapter- 2: Summary and Highlights4$250Free
Chapter- 3: Overview of Technologies and Global Markets18$406Free
Chapter- 4: Impact of COVID-19 Pandemic2$45Free
Chapter- 5: Pipeline Assessment and Analysis10$225Free
Chapter- 6: Regulatory Structure3$68Free
Chapter- 7: Market Breakdown by Women’s Health Disorder69$1,555Free
Chapter- 8: Market Breakdown by Region35$789Free
Chapter- 9: Pricing and Reimbursement4$90Free
Chapter- 10: Competitive Landscape and Key Developments14$316Free
Chapter- 11: Company Profiles69$1,555Free
Chapter- 12: Conclusions: Outlook for Women’s Health Therapeutics7$158Free
Chapter- 13: Appendix A: Glossary of Terms2$45Free
Chapter- 14: Appendix B: Industry and Professional Organizations9$203Free
Chapter- 15: Appendix C: Acronyms Used in This Report3$68Free
Published - May-2016| Analyst - Dr. Ritu Thakur Dangi| Code - BIO043F

Report Highlights

The global market for women’s health therapeutics will grow from nearly $33.0 billion in 2015 to nearly $40.6 billion by 2020, with a compound annual growth rate (CAGR) of 4.2% for the period of 2015-2020.

Report Includes

  • An overview of the global market for women's health therapeutics.
  • Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
  • Information on women's health disorder types including infertility, endometriosis, postmenopausal osteoporosis, menopause, and polycystic ovary syndrome (PCOS).
  • Detailed analysis of annual costs as well discussion on branded vs. generic options.
  • Specifics on market factors such as drivers, restraints, and competition.
  • Information on marketed as well as pipeline drugs and therapies.
  • Profiles of major players in the industry.
Published - May-2014| Analyst - Dr. Ritu Thakur Dangi| Code - BIO043E

Report Highlights

The global market for women’s health therapeutics was worth nearly $18.3 billion in 2012. The market is expected to increase from nearly $19 billion in 2013 to nearly $22.5 billion by 2018, a compound annual growth rate (CAGR) of 3.5% for the five-year period, 2013 to 2018.

Report Includes

  • An overview of the global therapeutics for women's health market.
  • Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
  • Information on women's health disorder types including infertility, endometriosis, postmenopausal osteoporosis, menopause, and polycystic ovary syndrome (PCOS).
  • Detailed analysis of annual costs as well discussion on branded vs. generics.
  • Specifics on market factors such as drivers, restraints, competition, and market shares.
  • Information on marketed as well as pipeline drugs and therapies.
Published - Mar-2009| Analyst - Melissa Elder| Code - BIO043D

Report Highlights

  • The U.S. market for therapeutics and diagnostics for women’s disorders was worth $29.9 billion in 2008. This should increase to $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
  • The rheumatoid arthritis and osteoporosis segment has the largest share of the market, generating $10.6 billion in 2008. This is expected to grow at a CAGR of 11.5% to reach $18.2 billion in 2013.
  • Reproductive related therapies and diagnostics currently have the second largest market share, worth $5.9 billion in 2008. This should reach $7.5 billion in 2013, for a CAGR of 5.0%.
Published - May-2005| Analyst - Melissa Elder| Code - BIO043C

Report Highlights

  • The total U.S. market for new therapeutics and diagnostics for women’s disorders was estimated at more than $25 billion in 2004 and is expected to reach nearly $41 billion in 2009, rising at an AAGR (average annual growth rate) of 10.3%.
  • Treatments for cancers specific to women will rise the fastest, at an AAGR of 12.6% and will lead revenues in 2009.
  • Reproductive-related therapies and diagnostics currently represent the largest market segment, but, rising at an AGR of 8.4%, will lag slightly by 2009.
  • Treatments for gynecological diseases and infections and for rheumatoid arthritis and osteoporosis also represent large market segments.
Published - Jan-2001| Analyst - Mary Anne Crandall| Code - BIO043B

Report Highlights

  • The total current U.S. market for new therapeutics and diagnostics for women's disorders in 1999 reached $16.9 billion at the manufacturers' level. The growing numbers of women combined with the growing trend to take an active role in healthcare has driven growth in this market. By 2005, it is anticipated that revenues will likely reach $31.9 billion, growing at an average annual rate of 8.7%.
  • The reproductive-related therapeutics and diagnostics holds the largest market revenues position representing 31.9% and accounting for $5.4 billion of the total in 1999. Large numbers of women in the baby boomer age group, coupled with large numbers of the mini-boomers (daughters of the baby boomer generation), contributed to the reproductive-related therapeutics and diagnostics' dominate role in 1999. It is anticipated that the reproductive-related therapeutics and diagnostics will remain the largest market share throughout the forecast period as it crosses $10 billion by 2005.

Therapeutics for Women's Health: Technologies and Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS